Navigation Links
Susan G. Komen Breast Cancer Foundation awards grant for imaging-agent research
Date:10/30/2008

CLEMSON Clemson University researchers developing imaging agents to allow a new method of detecting breast cancers have received $180,000 from the Susan G. Komen Breast Cancer Foundation. Breast cancer is the second leading cause of cancer deaths in American women.

The new method allows for a combination of light and MRI (magnetic resonance imaging) that may help researchers look at different parts of cells and tissues.

Clemson chemistry professor and principal investigator Ya-Ping Sun said the funding will play a major role in further developing Clemson technologies on fluorescent carbon nanomaterials, dubbed "carbon dots", by implanting magnetic elements into the dots. This will serve as a contrast agent for both light- and magnetic-imaging techniques for the early detection and diagnostics of breast cancers and beyond. Li Cao, a research scientist in Sun's research group, will carry out the research project.

"We're enhancing the chemistry and properties of these carbon quantum dots for their potential uses in diagnostics that essentially combine the capabilities of MRIs with those of optical imaging," said Sun. "It may be a more efficient, pinpointed way of detecting where the cancers are."

Imaging techniques such as mammography, specialized MRI and optical imaging all improve the chances of early detection. The complementary advantages of specialized MRI and fluorescence imaging can be especially beneficial to patients because of significant improvements in contrast and spacial resolution.

The carbon quantum dots are thousands of times smaller than the width of a human hair. When they are covered with special polymers, they begin to glow when exposed to light. The glow is continuous until the light source is removed. Materials such as antibodies or magnetic elements can be attached to the polymer coating. Sun said this could lead to better dyes for medical imaging. Since they are organic, the carbon dots are saf
'/>"/>

Contact: Ya-Ping Sun
syaping@clemson.edu
864-656-5026
Clemson University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. PRA International Adds Dr. Susan Stansfield as Executive Vice President
2. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
3. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
4. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
5. Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure
6. PNY Technologies and Susan G. Komen for the Cure Partner to Raise Awareness of Breast Cancer
7. Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer
8. Susan G. Komen for the Cures Phoenix Affiliate, State Officials, Survivors and Advocates Call for Action on Breast Cancer
9. Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries
10. In Celebration of Breast Cancer Awareness Month, Susan G. Komen for the Cure San Diego Announces Opportunities for San Diegans to Get Involved in the Fight Against Breast Cancer
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... announced that it has become a national sponsor o...profit organizations dedicated to arthritis resear... Delray Beach, FL (Vocus) November 27, 200...any specializing in the marketing and retail distr...nced today that is has become a national sponsor o...
(Date:11/27/2009)...conomic burdens, study predicts , , FRID...le with diabetes in the United States is expected ...icts. , That would bring the total by 2034 to a... 23.7 million today. , , At the same time, the c...the study also warns, rising from an estimated $11...
(Date:11/27/2009)...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E... (PRWEB) November 27, 2009 -- Voyant Health&trade...ds, Michigan) has licensed its TraumaCad Enterpris... Extend workflow solution, to allow its orthopedic...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...fluseasonuponus,it,smoreimportantthanevertoemployg...illness. ,, "Weneedtobeproactivenotonlytokeepou...esick,"saidEileenFinerty,RN,MS,CIC(certifiedininfe...ndoccupationalhealthatHospitalforSpecialSurgery(HS...neofthelowestinfectionratesofanyhospitalinthecount...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...ELPHIA (January 22, 2008) -- Researchers from the ...have used a novel molecular method to identify che...man bitter taste receptors. , The findings, publ...ste in particular. , Identification of bitter t...
...chers in the Department of Medicine and Department...e have discovered that chronic pain can be success... an effort to find a more effective treatment for ...ensory neuron targeting by self-complementary AAV8...
...da, MD (Jan. 18, 2008) The use of regular, long-t...ugs (NSAIDs) reduces the risk associated with colo...Gastroenterology , the official journal of the Ame... at doses that are higher than recommended over a ...
...l, January 22, 2007 An international research tea...de lUniversit de Montral (CHUM), has identified ne...e sclerosis (MS). In the February issue of Nature ... the nervous system that affects approximately 55,...
...dies sense painful stimuli through certain recepto...l organs. Specialized nerve fibers relay these sig... pain becomes conscious. The spinal cord is placed...nd at the Institute of Pharmacology and Toxicology...
...taking Nexavar need to be monitored closely, study...) -- ,A drug that prolongs the lives of patients w... of developing high blood pressure. , Patients ta...logy . , Nexavar is an anti-angiogenesis drug, mea...
Other Medicine News:Health News:Food peptides activate bitter taste receptors 2Health News:Researchers find relief for chronic pain 2Health News:Regular, long-term aspirin use reduces risk of colorectal cancer 2Health News:New therapeutic target for treatment of multiple sclerosis 2Health News:Nature publication on pain research 2Health News:Liver Cancer Drug Raises Blood Pressure 2
(Date:11/25/2009)...Calif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,ann...ny,sPROTECT-1(theProspectiveRandomizedOralTherapyE...CX282-B)inpatientswithmoderate-to-severeCrohn,sdis...tyandtolerabilityprofile.Thestudydemonstratedevide...tyasdefinedasa70-pointdecreaseintheCrohn,sDiseaseA...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Endologix,Inc.(Nasd...oraorticdisorders,announcedtodaythatithasfiledamot...nfringementlawsuitbroughtagainstitinOctober2009byC...CourtinIndianapolis,Indiana. ,, Endologixhasreq...sPatentandTrademarkOffice(USPTO)conductsproceeding...
(Date:11/24/2009)...24/PRNewswire-FirstCall/--AnadysPharmaceuticals,In...the21stAnnualPiperJaffrayHealthcareConferenceonTue...onferenceisbeingheldatTheNewYorkPalaceHotel.SteveW...adys,willprovideanoverviewofAnadysanditsclinicalde...atepresentationwillbesimultaneouslywebcastandcanbe...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2AMT Provides Business Update for the Third Quarter 2009 14895 1AMT Provides Business Update for the Third Quarter 2009 14895 2AMT Provides Business Update for the Third Quarter 2009 14895 3AMT Provides Business Update for the Third Quarter 2009 14895 45 exercises can reduce neck shoulder pain of women office workers 10780 15 exercises can reduce neck shoulder pain of women office workers 10780 25 exercises can reduce neck shoulder pain of women office workers 10780 3BioSoteria CEO to Present at Drug Safety Conference 14889 1BioSoteria CEO to Present at Drug Safety Conference 14889 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
Atria 3100 ECG
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: